Philip Quinlan

Philip Quinlan

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Cancer Cell
Verified
Journal Article
Closed access
JGJavier E. Girardini
Javier E. Girardini
MNMarco Napoli
Marco Napoli
SPSilvano Piazza
Silvano Piazza
ARAlessandra Rustighi
Alessandra Rustighi
CMCarolina Marotta
Carolina Marotta
GSGiannino Del Sal
Giannino Del Sal

8 November 2010 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
ATAlastair M Thompson
Alastair M Thompson
LJLee B Jordan
Lee B Jordan
PQPhilip Quinlan
Philip Quinlan
EAElizabeth Anderson
Elizabeth Anderson
ASAnthony Skene
Anthony Skene
TGthe Breast Recurrence in Tissues Study Group
the Breast Recurrence in Tissues Study Group
Introduction: Immunohistochemistry of primary breast cancer is routinely used to guide changes in therapy at the time of relapse. Retrospective reviews suggest that the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor type 2 (HER2) receptor may differ between the primary and loco-regional recurrence or distant metastases. The Breast Recurrence In Tissues Study (BRITS) was a large, multicentre, prospective study to examine changes in ER, PR and HER2. Methods: Matched primary and recurrent breast cancer tissue samples were prospectively collected from 205 women attending 20 institutions. Central laboratory immunohistochemical analysis of core biopsies and tissue microarrays of ER and PR using the Allred and Quickscore methods and HER2 (confirmed by fluorescence in situ hybridisation (FISH) for HER2 2+) were performed. Results: From 205 consenting women, 18 (8.8%) did not have recurrent disease on biopsy, 35 were ineligible, 13 had insufficient paired tissue and 2 were excluded for safety reasons. Paired samples from 137 women, mean age 62.6 years (range 27-87 years), 83/137 (60.6%) postmenopausal with a median 92.2 months (range 5-327 months) from primary to recurrence and 88 (64.2%) as locoregional recurrence were successfully analysed. A switch in receptor status, in either direction, by Allred score, was identified for ER in 14 patients (10.2%; P = 0.983 Wilcoxon sign rank test), PR in 34 (24.8%; P = 0.003 Wilcoxon sign rank test) and HER2 in 4 (2.9%; P = 0.074 Wilcoxon sign rank test). There was no difference between locoregional or distant recurrence in the proportion who switched. The switch in receptor status led to a change in the subsequent treatment plan for 24 patients (17.5%). Conclusions: This prospective study confirms retrospective evidence that the management of relapsed breast cancer should include confirmatory tissue sampling and identify switches of ER, PR or HER2 which change therapeutic management for one in six patients.

3 December 2013 in British Journal of Cancer
Verified
Journal Article
Open access
CPC A Purdie
C A Purdie
PQPhilip Quinlan
Philip Quinlan
LJL B Jordan
L B Jordan
AAA Ashfield
A Ashfield
SOS Ogston
S Ogston
ATA M Thompson
A M Thompson
Background: Methods: Results: Conclusion:

1 September 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SHSirwan M Hadad
Sirwan M Hadad
LBLee Baker
Lee Baker
PQPhilip Quinlan
Philip Quinlan
KRKatherine E Robertson
Katherine E Robertson
SBSusan E Bray
Susan E Bray
ATAlastair M Thompson
Alastair M Thompson
AMP-activated protein kinase (AMPK) acts as a cellular fuel gauge that responds to energy stress by suppressing cell growth and biosynthetic processes, thus ensuring that energy-consuming processes proceed only if there are sufficient metabolic resources. Malfunction of the AMPK pathway may allow cancer cells to undergo uncontrolled proliferation irrespective of their molecular energy levels. The aim of this study was to examine the state of AMPK phosphorylation histologically in primary breast cancer in relation to clinical and pathological parameters.

1 October 2012 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
EAEitan Amir
Eitan Amir
MCMark Clemons
Mark Clemons
CPColin A. Purdie
Colin A. Purdie
NMNaomi Miller
Naomi Miller
PQPhilip Quinlan
Philip Quinlan
ATAlastair M. Thompson
Alastair M. Thompson

23 September 2013 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MPM A Province
M A Province
MGM P Goetz
M P Goetz
HBHiltrud Brauch
Hiltrud Brauch
DFD A Flockhart
D A Flockhart
JHJ M Hebert
J M Hebert
TKT E Klein
T E Klein
The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta‐analysis on data from 4,973 tamoxifen‐treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor–positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was associated with poorer invasive disease–free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen duration, menopausal status, and annual follow‐up were not specified (criterion 2, n = 2,443; P = 0.25) or when no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy. Clinical Pharmacology & Therapeutics (2014); 95 2, 216–227. doi:10.1038/clpt.2013.186